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CancerThe mammalian family of mitogen-activated protein kinases (MAPKs) includes extracellular signal-regulated
kinase (ERK), p38, and c-Jun NH2-terminal kinase (JNK), with each MAPK signaling pathway consisting of at
least three components, a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K), and a MAPK. The MAPK
pathways are activated by diverse extracellular and intracellular stimuli including peptide growth factors,
cytokines, hormones, and various cellular stressors such as oxidative stress and endoplasmic reticulum
stress. These signaling pathways regulate a variety of cellular activities including proliferation, differentia-
tion, survival, and death. Deviation from the strict control of MAPK signaling pathways has been implicated
in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD),
amyotrophic lateral sclerosis (ALS) and various types of cancers. Persistent activation of the JNK or p38
signaling pathways has been suggested to mediate neuronal apoptosis in AD, PD, and ALS, whereas the ERK
signaling pathway plays a key role in several steps of tumorigenesis including cancer cell proliferation,
migration, and invasion. In this review, we summarize recent ﬁndings on the roles of MAPK signaling
pathways in human disorders, focusing on cancer and neurodegenerative diseases including AD, PD, and ALS.ase; ERK, extracellular signal-
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Mitogen-activated protein kinases (MAPKs) are serine-threonine
kinases that mediate intracellular signaling associated with a variety
of cellular activities including cell proliferation, differentiation, sur-
vival, death, and transformation [1–3]. The mammalian MAPK family
consists of extracellular signal-regulated kinase (ERK), p38, and c-Jun
NH2-terminal kinase (JNK; also known as stress-activated protein
kinase or SAPK). Each of these enzymes exists in several isoforms:
ERK1 to ERK8; p38-α, -β, -γ, and -δ; and JNK1 to JNK3 [3,4]. EachMAPK
signaling axis comprises at least three components: a MAPK kinase
kinase (MAP3K), a MAPK kinase (MAP2K), and a MAPK. MAP3Ks
phosphorylate and activateMAP2Ks, which in turn phosphorylate and
activate MAPKs (Fig. 1A). Activated MAPKs phosphorylate varioussubstrate proteins including transcription factors such as Elk-1, c-Jun,
ATF2, and p53. MAPK pathways are activated either as a result of a
series of binary interactions between the kinase components or
through the formation of a signaling complex containing multiple
kinases that is guided by a scaffold protein. Such scaffold proteins
mediate the activation of MAPK signaling pathways consisting of
speciﬁc kinase components. Kinase suppressor of Ras-1 (KSR) and
MEK partner 1 (MP1) function as scaffold proteins for the ERK sig-
naling pathway, whereas JNK-interacting proteins (JIPs) serve as
scaffold proteins for the JNK pathway. β-Arrestin 2 acts as a scaffold
protein for both the ERK and JNK signaling pathway [5,6] (Fig. 1B).
The JNK and p38 signaling pathways are activated by pro-
inﬂammatory cytokines such as tumor necrosis factor (TNF)-α and
interleukin (IL)-1β or in response to cellular stresses such as geno-
toxic, osmotic, hypoxic, or oxidative stress (Fig. 1A). The JNK pathway
consists of JNK, a MAP2K such as SEK1 (also known as MKK4) or
MKK7, and a MAP3K such as ASK1, MEKK1, mixed-lineage kinase
(MLK), or transforming growth factor-β-activated kinase 1 (TAK1)
[7]. In the p38 signaling pathway, distinct MAP2Ks such as MKK3 and
MKK6 activate p38 and are themselves activated by the sameMAP3Ks
(such as ASK1 and TAK1) that function in the JNK pathway. In the ERK
signaling pathway, ERK1 or ERK2 (ERK1/2) is activated by MEK1/2,
which in turn is activated by a Raf isoform such as A-Raf, B-Raf, or Raf-
1 (also known as C-Raf). The kinase Raf-1 is activated by the small
GTPase Ras, whose activation is mediated by the receptor tyrosine
kinase (RTK)-Grb2-SOS signaling axis [3]. Members of the Ras family
of proteins, including K-Ras, H-Ras, and N-Ras, play a key role in
transmission of extracellular signals into cells [8].
Fig. 1. Mitogen-activated protein kinase (MAPK) signaling pathways. A. MAPK signaling pathways mediate intracellular signaling initiated by extracellular or intracellular stimuli.
MAP3Ks, which are activated by MAP4Ks or GTPases, mediate phosphorylation and activation of MAP2Ks, which in turn phosphorylate and activate MAPKs. Activated MAPKs
phosphorylate various substrate proteins including transcription factors, resulting in regulation of a variety of cellular activities including cell proliferation, differentiation, migration,
inﬂammatory responses, and death. The mammalian MAPK family includes ERK, p38, and JNK. In the ERK signaling pathway, ERK1/2 is activated by MEK1/2, which is activated by
Raf. Raf is activated by the Ras GTPase, whose activation is induced by RTKs such as the epidermal growth factor receptor. The p38 and JNK pathways consist of a MAP3K such as
ASK1, MEKK1, or MLK3 as well as a MAP2K such as MKK3 or MKK6 for the p38 pathway or MKK4 or MKK7 for the JNK pathway. Activation by MAPK signaling cascades is achieved
either through a series of binary interactions among the kinase components or through formation of a multiple kinase complex mediated by a scaffold protein. B. Scaffold proteins
that facilitate activation of MAPK signaling pathways include JIP for the JNK signaling pathway, KSR and MP1 for the ERK signaling pathway, and β-arrestin 2 for the ERK and JNK
pathways.
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for phosphorylation of a MAP2K in the JNK or ERK signaling pathways
but also an E3 ubiquitin ligase activity that is attributable to its RING
domain. MEKK1 regulates cell adhesion and migration through
binding to several proteins such as RhoA, Rac, and actin [9]. Tumor
cell dissemination and lung metastasis were found to be substantially
delayed in MEKK1 knockout mice [10]. Apoptosis signal-regulating
kinase 1 (ASK1), a MAP3K in both the JNK and p38 signaling path-
ways, is activated in response to a variety of stressors including
reactive oxygen species (ROS), lipopolysaccharide (LPS), endoplasmic
reticulum (ER) stress, and Ca2+ inﬂux [11].
Consistent with their critical roles in key cellular activities,
including cell proliferation, differentiation, and survival or death,
the MAPK signaling pathways have been implicated in the pathogen-
esis of many human diseases. In this review, we summarize
recent ﬁndings on the roles of MAPK signaling pathways in human
disease, especially cancer and neurodegenerative diseases including
Alzheimer's disease, Parkinson's disease, and amyotrophic lateral
sclerosis.2. MAPK signaling in neurodegenerative diseases
2.1. Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease charac-
terized by cognitive and memory dysfunction that is thought to result
from the formation in the brain of both senile plaques containingamyloid-β (Aβ) and neuroﬁbrillary tangles containing the microtu-
bule-associated protein tau [12–14] (Fig. 2A).
Tau is present in a hyperphosphorylated form in neuroﬁbrillary
tangles, with its phosphorylation having been shown to be mediated
by several kinases including JNK, p38, and ERK [15,16]. Approximately
5% of patients with the familial form of AD harbor mutations in one of
the three genes encoding amyloid precursor protein (APP) [17],
presenilin-1 [18], or presenilin-2 [19], whereas most cases of sporadic
AD are thought to result from multiple gene defects [20]. APP is an
integral membrane protein that is cleaved sequentially by α-, β- (also
termed BACE1), and γ-secretases to produce non-amyloidogenic or
amyloidogenic Aβ proteins [21–23] (Fig. 2A). Amyloidogenic Aβ is
produced by β-secretase-mediated cleavage of APP at amino acid 83,
whereas non-amyloidogenic Aβ, which is not toxic to neurons, is
generated by α-secretase-mediated APP cleavage at amino acid 99
[24,25]. Aβ42, a major component of amyloid plaques in the AD brain,
is an Aβ peptide with 42 amino acids that is produced by the
amyloidogenic pathway. Although most Aβ proteins including Aβ42
and Aβ40 are secreted extracellularly, intracellular Aβ42 has been
shown to initiate mitochondrial oxidative stress and has been
implicated in the pathogenesis of AD [26,27].
Oxidative stress is thought to be a key risk factor in the
development of AD [28,29]. Such stress is often triggered by ROS
such as the hydroxyl radical, superoxide anion, and hydrogen
peroxide and is a typical activator of the JNK and p38 signaling
pathways in AD [30,31]. The activated MAPK signaling pathways are
thought to contribute to AD pathogenesis through various mechan-
isms including induction of neuronal apoptosis [32–35],
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[36,37], as well as phosphorylation and stabilization of APP, a
hallmark of AD, by JNK [38,39].
As mentioned above, ASK1 is a MAP3K in the JNK and p38 MAPK
pathways and is activated in response to oxidative stress [40].
Dimerization of APP, which is mediated by the Aβ42 portion of the
protein, induces the activation of the ASK1-MKK6-p38 signaling
pathway (Fig. 2B), resulting in tau phosphorylation [41]. ASK1 also
forms a signaling complex with APP, MKK6, JIP1, and JNK1 in the brain
of APP transgenic mice, and it induces either neuronal apoptosis or
neurite outgrowth after neural injury [42,43].
Aggregates of Aβ42 induce the activation of microglial macro-
phages, which then produce ROS and pro-inﬂammatory cytokines
such as TNF-α and IL-1β, all of which stimulate MAPK signaling
pathways (Fig. 2C). Under conditions of oxidative stress, JNK and p38
are activated and induce the expression of the β-secretase gene,
whereas ERK1/2 negatively regulates β-secretase expression [44]
(Fig. 2D). γ-Secretase is speciﬁcally activated by interferon-γ, IL-1β,
or TNF-α, and such cytokine-induced γ-secretase activity was found
to be blocked by a JNK inhibitor and to be enhanced by the expression
of a constitutively active form of MEKK1, implicating the JNK signaling
pathway in the regulation of γ-secretase activity [45]. Transforming
growth factor-β2 binds to APP, and this binding was shown to initiate
APP-dependent apoptosis through the activation of JNK and caspase-
3; the extent of cell death induced by mutant APP was markedly
greater than that induced by the wild-type protein [46].
Evidence thus suggests that MAPK signaling pathways may con-
tribute to the pathogenesis of AD through the regulation of neuronal
apoptosis, β- and γ-secretase activity, and phosphorylation of APP and
tau.2.2. Parkinson's disease
Parkinson's disease (PD) is the second most prevalent neurode-
generative disease after AD. PD is characterized by a progressive loss
of dopaminergic neurons in the substantia nigra and by the
accumulation in the brain of Lewy bodies (LBs), in which speciﬁc
proteins including modiﬁed α-synuclein are deposited. The symp-
toms of PD include movement disorders such as resting tremors,
postural abnormalities, rigidity, and akinesia, all of which develop as a
result of the loss of 50 to 70% of dopaminergic neurons [47,48].
To date, mutations in nine genes have been linked to PD. Those in
the genes for α-synuclein, ubiquitin carboxyl-terminal hydrolase L1
(UCHL1), leucine-rich repeat kinase 2 (LRRK2), GRB10-interacting
GYF protein 2 (GIGYF2), and HtrA2 (also known as Omi) are inherited
in an autosomal dominant manner, whereas those in the genes for
parkin, PTEN-induced kinase 1 (PINK1), DJ-1, and ATP13A2 are
responsible for autosomal recessive forms of PD [49].Fig. 2. Roles of MAPK pathways in the pathogenesis of Alzheimer's disease (AD), Parkinson's
β- and γ-secretases to produce the amyloidogenic Aβ proteins Aβ40 and Aβ42 in the ratio of 10
themicrotubule-associated protein tau that has been hyperphosphorylated by several kinases
the protein, activates the ASK1-MKK6-p38 cascade, which in turn phosphorylates tau, resulti
with the stabilization of phosphorylated APP being a hallmark of AD. C. Aggregates of Aβ42 act
as TNF-α and IL-1β, which together trigger activation of the JNK and p38 signaling cascade
activation of JNK and p38,which in turn increases transcription of theβ-secretase gene. In con
the production of Aβ. E. PD has been associated with functional defects in several genes. The
RING, a domain with E3 ubiquitin ligase activity; MLS, mitochondrial localization signal; KD,
induction of the pro-inﬂammatory cytokines IL-1β and TNF-α in microglia. α-Synuclein als
various cytokines may induce the death of neighboring dopaminergic (DA) neurons. G. α-
cytochrome c (CytC) from these organelles into the cytosol, resulting in the activation of th
pathway mediates the activation of p53, which then mediates induction of the pro-apopto
membrane. H. Mutants of parkin and DJ-1 activate the JNK or p38 signaling pathways to ind
dismutase (SOD1), TDP-43, and FUS (TLS) have been associatedwithALS. NLS, nuclear localiza
or p38 signaling pathways, resulting in aberrant phosphorylation and consequent aggregation
results in the persistent activation of p38 signaling in motor neurons. Activated p38 induc
transcriptional activation of the FasL gene, up-regulation of Fas signaling, and cell death. TF
associated degradation machinery, resulting in the activation of the ASK1-mediated cell deaThree synuclein genes, those for α-, β-, and γ-synucleins, have
been identiﬁed in humans. α-Synuclein is present in LBs in the brain
of PD patients and plays a key role in the development of PD [50],
although its cellular functions remain unclear. Mice lacking α-
synuclein manifest only mild abnormalities in neurotransmission
[51]. However, pathological forms of α-synuclein, including the
mutants A30P, E46K, and A53T, as well as the wild-type protein at
high levels that result from duplication or triplication of the α-
synuclein gene, are prone to form aggregates that trigger neuronal
apoptosis [52–54].
LBs contain α-synuclein that has been modiﬁed by phosphoryla-
tion [55,56], ubiquitination [57], nitration [58], or truncation [59]. The
high prevalence of such modiﬁed forms of α-synuclein in the brain of
PD patients suggests that they might contribute to neuronal toxicity
[60]. Increased levels ofα-synuclein are thought to be associated with
neuronal apoptosis induced by oxidative stress, neuroinﬂammation,
or dysfunction of MAPK signaling pathways [61–63].
Oxidative stress is a major cause of neuronal death in PD. Studies
with animal models of PD based on the neurotoxins 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine,
both of which elicit PD-like symptoms, have shown that ROS
production induced by the toxins results in the activation of microglial
cells, which subsequently attack neighboring dopaminergic neurons
[64–66]. α-Synuclein activates p38, ERK, and JNK pathways in human
microglial cells, resulting in the production of IL-1β and TNF-α and
consequent promotion of inﬂammation [67]. α-Synuclein also
induces the expression of IL-6 and intercellular adhesion molecule-1
(ICAM-1) in human astrocytes and thereby promotes chronic
inﬂammation (Fig. 2F). The up-regulation of these latter two proteins
is also associated with the activation of MAPK signaling pathways
[68]. Moreover, induction of both the release of cytochrome c from
mitochondria and mitochondrial oxidative stress appears to contrib-
ute to the regulation of neuronal apoptosis by α-synuclein [69,70]
(Fig. 2G).
MPTP, a neurotoxin, and pesticides such as rotenone and paraquat
have been widely used to elucidate the pathological mechanisms of
dopaminergic neuronal death in cellular and animal models of PD
[71,72]. Since the genetic relevance of PD occurrence is much lower
than its environmental causes at aged population, the exposure of the
widely used pesticides such as rotenone and paraquat has been
considered as a risk factor for PD [73,74]. Furthermore, Rotenone, but
not MPTP, can induce LB-like cytoplasmic inclusions in the substantia
nigra neurons [75]. MPTP induces the activation of ASK1 and thereby
positively regulates the JNK signaling pathway in dopaminergic
neurons [76,77]. 6-Hydroxydopamine, another neurotoxin that elicits
the death of dopaminergic neurons in animal models of PD, also
induces the activation of ASK1 in dopaminergic cells [78]. The p38
MAPK has also been shown to be activated in PD models and is
implicated in the mechanism of neuronal cell death [79,80]. Indeed,disease (PD), and amyotrophic lateral sclerosis (ALS). A. APP is sequentially cleaved by
:1. AICD, APP intracellular domain. Neuroﬁbrillary tangles found in the AD brain contain
including JNK, p38, and ERK. B. APP dimerization,which ismediated by the Aβ portion of
ng in the formation of neuroﬁbrillary tangles. JNK mediates the phosphorylation of APP,
ivatemicroglial macrophages, which produce ROS and pro-inﬂammatory cytokines such
s that may underlie the induction of neuronal death. D. Oxidative stress results in the
trast, ERK1/2 negatively regulates β-secretase expression.β-Secretase activity promotes
products of these PD-linked genes include α-synuclein, LRRK2, parkin, PINK1, and DJ-1.
kinase domain. F. α-Synuclein aggregates activate MAPK signaling, which mediates the
o induces the expression of IL-6 in astrocytes, resulting in chronic inﬂammation. These
Synuclein aggregates trigger ROS production by mitochondria as well as the release of
e caspase cascade and induction of apoptosis, in dopaminergic neurons. The p38 MAPK
tic protein Bax, which in turn promotes permeabilization of the mitochondrial outer
uce the death of dopaminergic neurons. I. Mutations in the genes for Cu/Zn superoxide
tion signal; RRM, RNA recognitionmotif. J. SOD1mutants induce the activation of the JNK
of neuroﬁlaments, inmotor neurons. K. Expression of SOD1mutants in transgenic mice
es the expression of iNOS and consequent production of NO, which in turn results in
, transcription factor. L. SOD1 mutants interact with Derlin-1, a component of the ER-
th pathway in motor neurons.
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the expression of the pro-apoptotic protein Bax, which in turn induces
the permeabilization of the mitochondrial outer membrane [81], in
dopaminergic neurons of the ventral midbrain in mice [82] (Fig. 2G).
A role for JNK in neuronal apoptosis has also been widely investigated
in both in vitro and in vivo models of PD [83,84]. Rotenone induces
apoptosis in dopaminergic SH-SY5Y cells through the activation of
JNK and p38 MAPKs [85] and its toxicity is prevented by basic
ﬁbroblast growth factor (bFGF), which activates the ERK1/2 and
phosphoinositide 3-kinase (PI3K) signaling pathways [86]. Paraquat
(1,1′-dimethyl-4,4′-bipyridium), which is chemically similar to MPTP,
also triggers dopaminergic cell death through the activation of the JNK
pathway [87–89]. Mice deﬁcient in JNK3 are more resistant to MPTP
than their wild-type littermates, suggesting that JNK inhibitors might
prove effective as therapeutic drugs for PD [90]. The pan-MLK
inhibitor CEP-1347 promotes cell survival in several dopaminergic
neuronal systems [91]. Although a clinical trial revealed CEP-1347 to
be ineffective for the treatment of patients with early PD [92], MLK
and JNK inhibitors may still hold promise as drugs to alleviate the
symptoms of PD [91,93].
Human LRRK2 is a 280-kDa protein that contains several func-
tional domains including leucine-rich repeats, a Ras-related GTPase
domain, a MAP3K domain, and WD-40 repeats [94]. Even though
several mutations in the Ras-related GTPase and MAP3K domains of
LRRK2 have been associated with familial or sporadic PD [95–97], the
contribution of each mutation to the disease process remains unclear.
LRRK2 was recently found to possess MAP3K activity for MAP2Ks
including MKK3/6 and MKK4/7 in vitro [98]. Further clariﬁcation of
the biological functions of LRRK2 may provide greater insight into its
role in the pathogenesis of PD.
Parkin is a multidomain E3 ubiquitin ligase [99] that mediates
the ubiquitination of several substrates including cyclin E [100],
synphilin [101], and LIM kinase 1 [102]. It also protects dopami-
nergic neurons from several neurotoxins and oxidative stress
[103,104]. JNK1 is highly activated in dopaminergic neurons
expressing loss-of-function mutants of parkin in Drosophila, result-
ing in neuronal death. Indeed, parkin prevents neuronal apoptosis
through inhibition of the JNK signaling pathway in a manner
dependent on its E3 ligase activity [105]. The neuroprotective
function of parkin has also been suggested to result from its
selective recruitment to damaged mitochondria, where it promotes
the autophagic removal of the ROS-generating organelles [106,107].
Thus, parkin appears to be involved in the regulation of mitochon-
drial turnover.
Deletion or down-regulation of the expression of the parkin gene
has been associated with several human cancers including the breast,
ovary, lung, and hepatocellular carcinomas, suggesting that parkin
may function as a tumor suppressor [108,109]. In the human brain,
parkin forms a complex with PINK1 and DJ-1 that degrades misfolded
proteins [110,111]. In addition, parkin compensates for mitochondrial
dysfunction associated with PINKmutants in Drosophila, suggestive of
genetic interaction between PINK1 and parkin [112].
DJ-1 is a neuroprotective protein that has both peroxidase and
transcriptional co-activator activities [113,114]. DJ-1 translocates to
mitochondria and protects neurons in the cellular response to
oxidative stress [115]. It also regulates the aggregation of α-
synuclein, with the expression of DJ-1 mutants having been found
to promote α-synuclein aggregation and toxicity [116]. In addition,
DJ-1 regulates inﬂammatory responses in astrocytes. DJ-1-deﬁcient
astrocytes thus produce 10 times as much nitric oxide (NO) in
response to LPS as do wild-type cells. The p38 signaling pathway
mediates the up-regulation of inducible NO synthase (iNOS) by
LPS [117]. DJ-1 also inhibits the JNK signaling pathway by directly
targeting MEKK1 [118]. Furthermore, TRAF- and TNF receptor-
associated protein (TTRAP), which protects cells from apoptosis
induced by proteasome impairment, has been found to associatewith DJ-1. A DJ-1 mutant (M26I/L166P) that binds to TTRAP to a
greater extent than does wild-type DJ-1, blocked the protective
activity of TTRAP by triggering the activation of JNK1 and p38 in a
TTRAP-dependent manner [119].
HtrA2 (or Omi) is a mitochondrial serine protease [120]. Charac-
terization of HtrA2 knockout mice has revealed that this protein has a
neuroprotective function [121]. The G399S mutation of HtrA2 results
in a decrease in protease activity and has been associated with
sporadic PD [122]. The role of HtrA2 in the PINK1-parkin pathway is
unclear, however [123]. PINK1 functionally interacts with HtrA2 to
protect dopaminergic neurons from apoptosis induced by oxidative
stress. HtrA2 is phosphorylated on serine-142 by p38-γ, and the
extent of this phosphorylation was found to be reduced in PD patients
with the PINK1 mutations C573R and Y431H, suggesting that the
PINK1-dependent phosphorylation of HtrA2 might regulate its
protease activity [124].
Together, these various observations suggest that MAPK signaling
pathways contribute to neuroinﬂammatory responses and neuronal
death triggered by α-synuclein aggregates or functional deﬁciencies
in parkin or DJ-1 in the pathogenesis of PD.3. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's
disease) is a progressive neurodegenerative disease characterized by
a selective loss of motor neurons that results in muscle atrophy,
paralysis, and, eventually, death [125,126]. Most cases of ALS are
sporadic, with ~10% of cases being inherited in a dominant manner as
a result of a familial mutation in the gene for Cu/Zn superoxide
dismutase (also known as superoxide dismutase 1, or SOD1) (Fig. 2I).
Recent studies have also implicated the nucleic acid-binding proteins
TDP-43 (TAR DNA-binding protein-43) [127] and FUS (fused in
sarcoma; also known as TLS, for translated in liposarcoma) [128] in
the pathogenesis of ALS, suggesting that a defect in RNA metabolism
may be a contributing factor [129]. However, the functions of TDP-43
and FUS in neurons remain unclear.
SOD1 is a metalloenzyme that catalyzes conversion of the super-
oxide anion to hydrogen peroxide [130]. It is unclear why mutation of
the SOD1 gene speciﬁcally causes the death of motor neurons, but it is
thought that such ALS-associated mutations result in a neurotoxic
gain-of-function of SOD1 [131].
Aberrant expression and activation of p38 MAPK in motor neurons
and microglia are thought to be important for ALS progression [132].
Persistent activation of p38 correlates with degeneration of motor
neurons in transgenic mice expressing the G93A mutant of SOD1
[133,134]. Moreover, a p38 MAPK inhibitor, SB203580, prevents the
apoptosis of motor neurons induced by mutant SOD1 [135]. Both p38
and JNK1 are also implicated in cytoskeletal abnormalities of spinal
motor neurons, a feature of familial and sporadic ALS, through
aberrant phosphorylation and consequent aggregation of neuroﬁla-
ments [136–138] (Fig. 2J).
Signaling by p38 MAPK mediates Fas-dependent apoptosis
through up-regulation of NO production in motor neurons
[139,140]. Exogenous NO also induces expression of Fas ligand
(FasL) and thereby stimulates Fas signaling, which triggers activation
of the p38 pathway and NO synthesis (Fig. 2K). Motor neurons of
transgenic mice expressing mutant SOD1 (G93A or G85R) are more
sensitive to NO than are those of control mice.
SOD1 mutants including A4V, G85R, and G93A interact with
Derlin-1, a component of the ER-associated degradation machinery
[141], resulting in the activation of the ASK1-mediated cell death
pathway in motor neurons [142] (Fig. 2L). ASK1 is associated with the
mechanism of ER stress-induced neuronal cell death [143]. The
pathological mechanisms of MAPK signaling in ALS are summarized in
Fig. 2I–L.
401E.K. Kim, E.-J. Choi / Biochimica et Biophysica Acta 1802 (2010) 396–4054. MAPK signaling in cancer
Many of the cancer-associated mutations of components of MAPK
signaling pathways have been found in Ras and B-Raf, both of which
participate in the ERK signaling pathway [3,144]. Mutations of K-Ras
occur frequently in many human cancers including those of the lung
and colon [145]. Indeed, K-Ras mutations have been detected in ~50%
of colon cancers, in which mutations of N-Ras are rare [8]. Transgenic
mice expressing an activated form (G12D) of K-Ras manifest MEK-
dependent hyperproliferation of colonic epithelial cells, whereas
expression of the corresponding activated form (G12D) of N-Ras did
not have such an effect, suggesting that K-Ras(G12D), but not N-Ras
(G12D), activates the MEK-ERK signaling pathway and thereby
promotes the proliferation of colonic epithelial cells [146,147].
Activated MEK1/2 has also been shown to up-regulate the expression
of matrix metalloproteinases and to protect cancer cells from anoikis,
or detachment-induced apoptosis [148].
Mutations in the B-Raf gene are responsible for ~66% of malignant
melanomas [149]. The substitution of glutamate for valine at amino
acid 600 (V600E) of B-Raf is the most common of these mutations and
results in constitutive activation of B-Raf and the ERK signaling
pathway [150]. Mutations of B-Raf that do not affect its kinase activity
can also increase MEK-ERK signaling as a result of the formation of a
heterodimer between the mutant B-Raf and Raf-1 [151]. Mutations of
the Raf-1 gene are also found in acute myeloid leukemia [152].
The ERK signaling pathway plays a role in several steps of tumor
development. The phosphorylation by ERK of proteins such as myosin
light chain kinase, calpain, focal adhesion kinase, and paxillin [153]
promotes cancer cell migration. The ERK pathway also induces the
expression of matrix metalloproteinases and thereby promotes the
degradation of extracellular matrix proteins and consequent tumor
invasion [154]. Furthermore, ERK1/2 signaling regulates the activities
and levels of Bcl-2 family proteins such as the pro-apoptotic protein
BIM and the anti-apoptotic protein MCL-1, thereby promoting the
survival of cancer cells [155]. ERK thus mediates phosphorylation of
the transcription factor FOXO3A, which results in proteasome-
dependent degradation of the phosphorylated FOXO3A [156] and
consequent down-regulation of FOXO3A-dependent transcription of
the BIM gene [157]. ERK also phosphorylates MCL-1 on threonine-163
in the PEST domain, resulting in stabilization of MCL-1 and promoting
the survival of tumor cells. MCL-1 expression is increased in several
types of cancer and is associated with poor prognosis and resistance
to anticancer drugs [158]. The ERK signaling pathway is therefore
considered a prominent therapeutic target for the development of
chemotherapeutic drugs, with sorafenib, a Raf inhibitor, being one of
the most efﬁcient such drugs available [159].
Mutations in the epidermal growth factor receptor (EGFR), which
activates the ERK pathway, occur frequently in the lung and colorectal
cancers [160,161]. Abnormal activation of EGFR has been demon-
strated in ~80% of cases of non-small cell lung cancer [162]. The most
common mutation of EGFR is an in-frame deletion in the tyrosine
kinase domain, which results in activation of downstream signaling
such as that mediated by the PI3K-Akt and Raf-MEK-ERK pathways
[163]. Geﬁtinib and erlotinib, both of which are inhibitors of the
tyrosine kinase activity of EGFR, are used to block the proliferation of
non-small cell lung cancer cells [164]. Components of signaling
pathways activated by EGFR have also received great attention as
potential targets for the development of new therapeutic drugs for
lung cancer [165,166].
5. Conclusion
MAPK signaling pathways have been implicated in the pathogen-
esis of a variety of human disorders including cancer and neurode-
generative diseases such as AD, PD, and ALS. In AD, activation of MAPK
cascades contributes to disease progression through regulation ofneuronal apoptosis, β- and γ-secretase activity, and phosphorylation
of APP and tau. Inhibitors for ERK1/2, MEK, or JNK, all of which
contribute to the pathological hyperphosphorylation of tau, have been
widely investigated as potential therapeutic drugs for AD [167,168].
Inhibitors of p38 MAPK are also considered as potential drugs for AD,
given that the p38 pathway plays a key role in the Aβ42-induced
production of pro-inﬂammatory cytokines [169]. In addition, D-JNKI1,
a peptide inhibitor of JNK1, has been shown to reduce the levels of
mature and secreted forms of APP in cultured neurons [170]. The
development of a single agent to treat the symptoms of PD is likely to
prove difﬁcult because of the genetic complexity of this disease [171].
MLK isoform-speciﬁc inhibitors such as CEP-5104 and CEP-6331 have
been investigated in the mouse MPTP model of PD in an attempt to
develop second-generation drugs based on the pan-MLK inhibitor
CEP-1347 [172]. Aberrant expression and activation of p38 MAPK
have been demonstrated in motor neurons and microglia of ALS
patients. Several compounds including p38 inhibitors are under
investigation as potential therapeutic agents against ALS [135]. The
ERK signaling pathway plays a central role in several steps of cancer
development, including cancer cell migration and the development of
resistance to apoptosis, such as that mediated by phosphorylation and
consequent stabilization of the anti-apoptotic protein MCL-1. Inhibi-
tors of the ERK signaling pathway are thus good candidates for the
development of anticancer agents [173].
MAPK signaling pathways are also associated with the pathogen-
esis of several other chronic and genetic diseases such as Crohn's
disease, polycystic kidney disease, and the Ras-MAPK syndromes. A
clinical trial of CNI-1493, a JNK and p38 inhibitor, revealed beneﬁcial
effects on ulcer healing in patients with Crohn's disease, a chronic
inﬂammatory bowel condition [174]. Polycystic kidney disease
actually comprises a large family of genetic diseases characterized
by renal failure. The Ras-MAPK signaling pathway has been implicated
in the pathogenesis of polycystic kidney disease in studies with
transgenic mice expressing H-Ras [175]. Germline mutation of the H-
Ras gene has also been identiﬁed in Costello syndrome. Furthermore,
dysregulation of the Ras-MAPK signaling pathway has been identiﬁed
as a principal cause of the Ras-MAPK syndromes, which include
Noonan, LEOPARD, Costello, and cardio-facio-cutaneous syndromes as
well as neuroﬁbromatosis type I [176].
Given that the same components of MAPK signaling pathways act
differentially in the pathogenic mechanisms of many human diseases,
knowledge of the tissue- and disease-speciﬁc regulatory mechanisms
for MAPK signaling pathways might provide clues for the develop-
ment of new therapeutic drugs for human diseases.
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